Apellis Pharmaceuticals Inc (APLS)

33.45 +0.29 (+0.87%) USD  |  NASDAQ  |  Jan 03, 16:00
33.45 0.00 (0.00%) After-Hours: 20:00
More

Apellis Pharmaceuticals Research and Development Expense (Quarterly): 88.57M for Sept. 30, 2024

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for APLS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Biogen Inc 542.70M
Biomarin Pharmaceutical Inc 184.90M
Ionis Pharmaceuticals Inc 219.76M
QuidelOrtho Corp 55.90M
Moderna Inc 1.137B